Accelerating a complex rare disease study

Case study

Overview

ICON partnered on a global rare disease study in osteogenesis imperfecta, supporting feasibility, site identification and early site activation across 19 countries in multiple regions. The program required rapid identification of highpotential sites and delivery across parallel phase 2 and phase 3 pathways, with multiple interim analyses driving regulatory decisions. Operating in a constrained patient population with complex protocol requirements, ICON’s proactive and adaptive delivery model maintained momentum and ensured data readiness.

  • 2x

    enrolment performance versus feasibility projection
  • 184

    participants enrolled across phase 2-3
  • 11%

    screen failure rate
  • 52

    sites activated globally
  • 6

    month window for multiple critical milestones

Challenges

Sponsor enrolment projections exceeded historical benchmarks for this indication, increasing pressure on delivery from the outset. In addition to external factors that intensified this challenge, including COVID-19 disruptions during startup, the study combined several structural barriers to recruitment: 

  • A placebo-controlled design in a predominantly pediatric indication 
  • Requirement to pause standard of care treatments 
  • High participant burden including frequent visits, x-ray requirements and infusion schedules 

Operational intensity across overlapping milestones 

The program design included multiple critical milestones within a six-month window, including interim analyses, database locks and regulatory checkpoints. The phase 2 and phase 3 activities were initially treated as sequential rather than parallel deliverables, creating bottlenecks in data cleaning, reconciliation and resourcing under timeline pressure. 

Late protocol amendments and eCRF updates introduced significant retrospective data entry and verification requirements, increasing workload and risk of error. 

Limited visibility across vendor-managed data 

Imaging data was critical to primary endpoints. In this study, imaging data was managed through external vendors, with complete image delivery occurring later than planned. Limited oversight, fragmented reporting and long turnaround times reduced transparency and constrained ICON’s ability to mitigate risk. 

The sponsor added reviews for existing data two weeks prior to IA2 deadline that compounded downstream workloads:

  • 1,500 sponsor data review queries and 760 EDC queries, which created 1,785 new pages of SDV, requiring manual reconciliation across multiple reports and systems

The increased pressure on IA2 results added further operational burden for both the Clinical Operations and Clinical Data Solutions teams.

Solution

Solution Building recruitment momentum 

ICON implemented a hybrid feasibility and site identification model to prioritise high-performing sites early in the process which improved recruitment momentum and contributed to lower screen failure rates. To maintain this momentum, ICON introduced structured pre-screening and patient tracking, prioritised insight-led site engagement including weekly discussions with initiated sites to enrol participants quickly. 

We worked closely with sponsor-led referral and outreach initiatives including: 

  • Physician engagement and patient diagnostic team outreach 
  • Patient Recruitment Liaison monthly site check-ins 
  • Website and social media ads 

Adaptive execution across data, timelines, and a fragmented vendor landscape 

ICON responded to evolving study demands with a flexible operating model that allowed the team to reprioritise datasets aligned to critical milestones, reallocate resources, and deploy manual tracking tools to cover for system limitations. 

Despite compressed timelines, the team completed large-scale SDV and data reconciliation activities within compressed timelines, maintaining readiness for interim analyses. 

ICON created workarounds to improve oversight of key functions owned by external vendors, including the critical imaging data. These governance measures ensured continued progress even where upstream processes were outside ICON’s control: 

  • Structured internal tracking of imaging data status 
  • Active coordination between sites, sponsor and vendors 
  • Targeted follow-up to accelerate query resolution

Outcome

Despite sustained operational intensity, ICON: 

  • Met full recruitment targets for phase 2 and phase 3 
  • Delivered multiple interim milestones within a condensed timeframe 
  • Completed extensive SDV and data cleaning to ensure analysis readiness 

ICON improved enrolment performance, ultimately delivering 188 randomised participants across 50 sites. Measurable benefits to enrolment included: 

  • Enrolment rate of 0.42 patients per site per month—nearly double the projected rate of 0.23 
  • Low screen failure rate of just 11% 
  • Minimal dropout rate of just 0.013% per site per month 

Even as requirements evolved and vendor constraints added complexity, ICON maintained study progression and data integrity through adaptive resourcing, proactive site and patient engagement, and continuous management of data and vendor dependencies. 

By combining data-led insight, adaptive execution and operational resilience, ICON enables sponsors to progress with confidence in complex, time-critical environments.

Looking ahead

Planning a complex rare disease study? Connect with our Rare Disease team to learn how ICON can help you navigate operational complexity, accelerate delivery and maintain confidence in critical milestones

For more information

Contact us